COMMUNIQUÉS West-GlobeNewswire

Onconova Therapeutics, Inc. to Present at the NobleCON 15th Annual Investor Conference in Fort Lauderdale, FL
22/01/2019
NEWTOWN, Pa., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today [...]
Translate Bio Announces FDA Clinical Hold on Investigational New Drug Application (IND) for MRT5201 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
22/01/2019
LEXINGTON, Mass., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat [...]
Cytokinetics Announces Receipt of FDA Feedback Regarding Reldesemtiv in Patients With SMA
22/01/2019
Six Minute Walk Test Acceptable as Primary Efficacy Endpoint for Potential Registration Program SOUTH SAN FRANCISCO, Calif., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced [...]
BioCorRx Awarded NIDA Grant of Approximately $5.7 Million for BICX102, a Sustained Release Naltrexone Implant for the Treatment of Opioid Use Disorder
22/01/2019
ANAHEIM, CA, Jan. 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of advanced solutions in the treatment of substance use disorders, announced today [...]
TG Therapeutics Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Umbralisib for the Treatment of Marginal Zone Lymphoma
22/01/2019
Breakthrough Therapy Designation granted based on interim data from the Marginal Zone Lymphoma cohort of the UNITY-NHL trial NEW YORK, Jan. 22, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a [...]
IRADIMED CORPORATION to Hold 2018 Fourth Quarter Financial Results Conference Call on February 6th
22/01/2019
WINTER SPRINGS, Fla., Jan. 22, 2019 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2018 fourth quarter financial results before the market opens on Wednesday, [...]
Voyager Therapeutics Appoints Robert Hesslein as General Counsel
22/01/2019
CAMBRIDGE, Mass., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today [...]
Patient-Level Survival Analysis Demonstrates No Link Between Paclitaxel Dose and Mortality in Patients Treated with IN.PACT Admiral DCB
22/01/2019
Data Presented Today at LINC Reiterate Commitment to Patient Safety and Data Transparency DUBLIN and LEIPZIG, Germany - January 22, 2019 - Medtronic plc (NYSE:MDT) today announced new data shared on the IN.PACT(TM) [...]
Genmab Announces 2018 Net Sales Figures for DARZALEX® (Daratumumab)
22/01/2019
Company Announcement Net sales of DARZALEX in 2018 totaled USD 2,025 million Genmab receives royalties on worldwide sales from Janssen Biotech, Inc. Copenhagen, Denmark; January 22, 2019 – Genmab A/S (Nasdaq Copenhagen [...]
FDA Accepts IND Application for Cerecor’s Investigational Drug CERC-801 for the treatment of PGM1 Deficiency
22/01/2019
ROCKVILLE, Md., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in [...]
MediWound Announces Positive Top-Line Results from Its Pivotal Phase 3 Study (DETECT) in NexoBrid® for Eschar Removal of Severe Thermal Burns
22/01/2019
Met Primary and All Secondary Endpoints with Statistically Significant Results Compared with Control Group Conference call with MediWound management and U.S. key opinion leader begins today, January 22, 2019 at 10:00 a. [...]
CorVel Announces Quarterly Earnings Release Webcast
22/01/2019
IRVINE, Calif., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Event: Quarterly Earnings Release Webcast Hosts: Gordon Clemons, Chairman Michael Combs, President and Chief Executive Officer Date: Tuesday, February 5, 2019 Time: 11: [...]
EMA Grants Orphan Drug Designation to TLC178 for the Treatment of Soft Tissue Sarcoma
22/01/2019
TAIPEI, Taiwan and SOUTH SAN FRANCISCO, Calif., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development [...]
Transactions in relation to share buyback program
22/01/2019
Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]
Oasmia Pharmaceutical AB’s (publ, ”Oasmia”) decision to cancel the extraordinary general meeting on January 25, 2019
22/01/2019
The proposition on a new board of directors in Oasmia presented by Arwidsro Investment AB and Per Arwidsson (jointly “Arwidsro”) only a short period before the planned general meeting does not comply with Nasdaq [...]
Immunicum AB (publ) Announces Upcoming Investor Events in January
22/01/2019
Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management [...]
ACACIA PHARMA ANNOUNCES SUPPORTIVE CARDIAC SAFETY DATA FOR BARHEMSYS™
22/01/2019
Cambridge, UK and Indianapolis, US – 22 January 2019: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH) announces results from its latest study of BARHEMSYS™ (intravenous amisulpride), its anti- [...]
Bone Therapeutics announces 2019 business outlook and reports year-end 2018 cash position
22/01/2019
Regulated information Phase IIA results with ALLOB in patients undergoing a spinal fusion procedure expected mid-2019 CTA submission planned in H2 2019 to start delayed-union fractures study with ALLOB Phase III study [...]
Bone Therapeutics annonce ses perspectives d’affaires pour 2019 et dresse son bilan de trésorerie
22/01/2019
Information réglementée Résultats de la phase IIA d’ALLOB pour les patients suivant une procédure de fusion vertébrale attendus pour la mi-2019 Demande d’autorisation d’essai clinique (CTA) pour l’étude d’ALLOB dans les [...]

Pages